Annual Report

Name: Global Corporate Sustainability Reports Database
Creator: SustainabilityReports.com
License: https://creativecommons.org/licenses/by/4.0/

Overview

The report describes Immutep's transition into a Phase III biotechnology company, including first-patient dosing in the global TACTI-004 trial. It also highlights INSIGHT-003 response and disease-control results, 17 new patents, and total revenue and other income of A$10.33 million for FY2025.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 30 June 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services